A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis

Summary

To explore the safety of FE 999322 (microbiota suspension) and FE 999324 (microbiota capsule) versus placebo in subjects with active mild to moderate ulcerative colitis (UC).

Timeline

Start

2024-03-12

Primary completion

2026-01-15

Completion

2026-01-15

Outcome

Outcome not reported

Stopped (Business): “Not due to safety concerns, but changes in strategy which this trial no longer fulfills.”

Drugs

Indications